ArticleArchives of medical science : AMS2026
Hepatitis E virus (HEV) as an emerging challenge in Poland: a narrative review of epidemiological and clinical data.
Article in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Manuscripts on hepatitis E virus (HEV) epidemiology in Poland indexed in PubMed were analyzed in the context of current clinical and biological knowledge and epidemiological data from other regions of Europe and worldwide. The analyzed data indicate a high frequency of IgG HEV in Poland compared to other European countries and parts of the world, on average exceeding 40%. In some regions, almost 60% of the population has evidence of prior infection. It has been estimated based on the frequency of acute phase markers that at least 113,000 residents may acquire HEV infection annually. These findings support the need to improve availability of HEV diagnostics, increase physicians' awareness, and take into account HEV infection as an etiological factor of numerous diseases. Preventive measures, especially in high-risk groups, as well as further research on the clinical significance of HEV and on effective therapeutic management, should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.